References
- Hunter T, Cooper JA. Protein-tyrosine kinases. Annu Rev Biochem 1985;54:897–930. doi:10.1146/annurev.bi.54.070185.004341.
- Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999 Feb;21(2):187–190. doi:10.1038/5971.
- Tullemans BME, Heemskerk JWM, Kuijpers MJE. Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. J Thromb Hae Most 2018 Sep;16(9):1686–1699. doi:10.1111/jth.14225.
- Turro E, Greene D, Wijgaerts A, Thys C, Lentaigne C, Bariana TK, Westbury SK, Kelly MK, Selleslag D, Stephens JC, et al. A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding and bone pathologies. Sci Transl Med 2016;8:328ra30. doi:10.1126/scitranslmed.aad7666.
- Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005;13:861–871. doi:10.1016/j.str.2005.03.012.
- Ayrapetov MK, Wang YH, Lin X, Gu X, Parang K, Sun G. Conformational basis for SH2-Tyr(P)527 binding in Src inactivation. J Biol Chem 2006;281:23776–23784. doi:10.1074/jbc.M604219200.
- Freson K, Turro E. High-throughput sequencing approaches for diagnosing hereditary bleeding and platelet disorders. J Thromb Haemost 2017 Jul.;15(7):1262–1272. doi:10.1111/jth.13681.
- Lentaigne C, Freson K, Laffan MA, Turro E, Ouwehand WH. Inherited platelet disorders: toward DNA-based diagnosis. Blood 2016;127:2814. doi:10.1182/blood-2016-03-378588.